TUDCA + SP failed in ALS (phase 3) and was withdrawn from the market. The company behind it believes it cannot help in PD, and they’re looking at PSP instead: Pipeline | Amylyx
There’s an ongoing trial of UDCA in PD in the UK.
1 Like
I have recently stopped taking TUDCA myself. I have not spotted anything that I would particularly link to it. That does not necessarily mean anything as I keep track of a lot of things and there are continual changes going on. I have dropped it to see if that changes anything - which it would do slowly if at all.
1 Like
On air pollution:
- Prominent role of PM10 in the link between air pollution and incident Parkinson’s Disease 2025: “The association was confirmed testing average PM10 levels during follow-up (18[13–24]% increase of PD risk per 1 μg/m3 increase of PM10).”
- Causal relationship between nitrogen dioxide and the risk of Parkinson’s disease: Evidence from a Mendelian randomization study 2025: “The main results of the IVW method (odds ratio: 4.701; 95% CI: 1.127–19.615, P = .034) showed evidence for a causal relationship between NO2 exposure and the risk of PD. Heterogeneity analyses was conducted using the MR-Egger method (Cochran’s Q = 1.155; P = .764) and IVW (Cochran’s Q = 1.356; P = .852) demonstrated no statistically significant heterogeneity among the selected SNPs. We employed MR-Egger regression (β intercept = −0.026; SE = 0.058; P = .684) and the MR-PRESSO global test (P = .840), which revealed no significant impact of pleiotropy on the results of the MR evaluation. Based on MR analysis, higher levels of NO2 exposure are causally associated with an increased risk of PD. Consequently, mitigating air pollution could be an important strategy for reducing the risk of PD.”
Urate predicts rate of clinical decline in Parkinson disease
Unfortunately: Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial 2021
Among patients recently diagnosed as having PD, treatment with inosine, compared with placebo, did not result in a significant difference in the rate of clinical disease progression.
2 Likes
Looks like tryptophan processing is harmed by PM10 ( —> melatonin).
We just finished fundraising a worm lifespan study of a promising longevity molecule indolepropionamide (IPAM). I’ve been doing an extensive deep dive into all literature available on IPAM and related indole molecules for longevity and health and it might be something to keep an eye on for Parkinson’s. This class of molecules has shown some potential for it, and Alzheimer’s.
I’ll be presenting all of the information I find once the study is complete. It should be good.
Here is my original post: 268% Median Lifespan Increase with Indolepropionamide aka Indole-3-propionamide or IPAM – What this is, and why more studies NEED to be funded! - #121 by Neo
This study outlines an indole derivative showing promise for Parkinson’s:
Neuroprotection of Indole-Derivative Compound NC001-8 by the Regulation of the NRF2 Pathway in Parkinson’s Disease Cell Models https://onlinelibrary.wiley.com/doi/10.1155/2019/5074367
1 Like